Treating multiple sclerosis with natalizumab

References

• Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N. Engl. J. Med.343(13), 938–952 (2000).
   PubMed Web of Science ®Google Scholar
• Lassmann H, Brück W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol. Med.7(3), 115–121 (2001).
   PubMed Web of Science ®Google Scholar
• Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med.338(5), 278–285 (1998).
   PubMed Web of Science ®Google Scholar
• Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr. Opin. Neurol.12(3), 295–302 (1999).
   PubMed Web of Science ®Google Scholar
• Bjartmar C, Trapp BD. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr. Opin. Neurol.14(3), 271–278 (2001).
   PubMed Web of Science ®Google Scholar
• Hemmer B, Archelos JJ, Hartung HP. New concepts in the immunopathogenesis of multiple sclerosis. Nat. Rev. Neurosci.3(4), 291–301 (2002).
   PubMed Web of Science ®Google Scholar
• The IFNB Multiple Sclerosis Study Group. Interferon β-1b is effective in relapsing–remitting multiple sclerosis. Clinical results of a multicenter, randomized, double-blind, placebo controlled trial. Neurology43, 655–661 (1993).
   PubMed Web of Science ®Google Scholar
• The IFNb Multiple Sclerosis Study Group and The Univesity of British Columbia MS/MRI Analysis Group. Interferon β-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology45, 1277–1285 (1995).
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis. Ann. Neurol.39, 285–294 (1996).
   PubMed Web of Science ®Google Scholar
• PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomized double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet352, 1498–1504 (1998).
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing remitting multiple sclerosis: results of a Phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology45, 1268–1276 (1995).
   PubMed Web of Science ®Google Scholar
• Marriott JJ, Miyasaki JM, Gronseth G, O’Connor PW. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Evidence report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology74(18), 1463–1470 (2010).
   PubMed Web of Science ®Google Scholar
• Rudick RA, Cutter GR, Baier M et al. Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients. Mult. Scler.11(6), 626–634 (2005).
   PubMed Web of Science ®Google Scholar
• Bermel RA, Weinstock-Guttman B, Bourdette D et al. Intramuscular interferon β-1a therapy in patients with relapsing–remitting multiple sclerosis: a 15-year follow-up study. Mult. Scler.16(5), 588–596 (2010).
   PubMed Web of Science ®Google Scholar
• Kappos L, Traboulsee A, Costantinescu C et al. Long-term subcutaneously interferon β-1a therapy in patients with relapsing-remitting MS. Neurology67, 944–953 (2006).
   PubMed Web of Science ®Google Scholar
• Ebers GC, Rice G, Konieczny A et al. The interferon β-1b 16-year long-term follow-up study: the final results. Neurology66(Suppl. 2), A32 (2006).
   Web of Science ®Google Scholar
• Ebers GC, Traboulsee A, Li D et al. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNβ-1b trial. J. Neurol. Neurosurg. Psychiatry81(8), 907–912 (2010).
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Ford CC et al. Glatiramer acetate (Copaxone), comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial. Mult. Scler.9(6), 585–591 (2003).
   PubMed Web of Science ®Google Scholar
• Johnson KP, Ford CC, Lisak RP, Wolinsky JS. Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. Acta Neurol. Scand.111(1), 42–47 (2005).
   PubMed Web of Science ®Google Scholar
• Ford CC, Johnson KP, Lisak RP et al. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult. Scler.12(3), 309–320 (2006).
   PubMed Web of Science ®Google Scholar
• Ford C, Goodman AD, Johnson K et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult. Scler.16(3), 342–350 (2010).
   PubMed Web of Science ®Google Scholar
• Trojano M, Pellegrini F, Fuiani A et al. New natural history of interferon-β-treated relapsing multiple sclerosis. Ann. Neurol.61(4), 300–306 (2007).
   PubMed Web of Science ®Google Scholar
• Rudick RA, Stuart WH, Calabresi PA et al. Natalizumab plus interferon β-1a for relapsing multiple sclerosis. N. Engl. J. Med.354, 911–923 (2006).
   PubMed Web of Science ®Google Scholar
• Polman CH, O’Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med.354, 899–910 (2006).
   PubMed Web of Science ®Google Scholar
• Van Assche G, Van Ranst M, Sciot R et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N. Engl. J. Med.353(4), 362–368 (2005).
   PubMed Web of Science ®Google Scholar
• Yousry TA, Major EO, Ryschkewitsch C et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med.354(9), 924–933 (2006).
   PubMed Web of Science ®Google Scholar
• Iaffaldano P, D’Onghia M, Trojano M. Safety profile of Tysabri: international risk management plan. Neurol Sci.30(Suppl. 2), S159–S162 (2009).
   PubMedGoogle Scholar
• Kivisäkk P, Healy BC, Viglietta V et al. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology72(22), 1922–1930 (2009).
   PubMed Web of Science ®Google Scholar
• Stüve O, Marra CM, Jerome KR et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann. Neurol.59(5), 743–747 (2006).
   PubMed Web of Science ®Google Scholar
• Krumbholz M, Meinl I, Kümpfel T, Hohlfeld R, Meinl E. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology71(17), 1350–1354 (2008).
   PubMed Web of Science ®Google Scholar
• Mellergård J, Edström M, Vrethem M, Ernerudh J, Dahle C. Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. Mult. Scler.16(2), 208–217 (2010).
   PubMed Web of Science ®Google Scholar
• Ramos-Cejudo J, Oreja-Guevara C, Stark Aroeira L, Rodriguez de Antonio L, Chamorro B, Diez-Tejedor E. Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanism. J. Clin. Immunol.31(4), 623–631 (2011).
   PubMedGoogle Scholar
• Lindberg RL, Achtnichts L, Hoffmann F, Kuhle J, Kappos L. Natalizumab alters transcriptional expression profiles of Blood cell subpopulations of multiple sclerosis patients. J. Neuroimmunol.194(1–2), 153–164 (2008).
   PubMed Web of Science ®Google Scholar
• Stüve O, Gold R, Chan A, Mix E, Zettl U, Kieseier BC. α4-Integrin antagonism with natalizumab: effects and adverse effects. J. Neurol.255(Suppl. 6), 58–65 (2008).
   PubMed Web of Science ®Google Scholar
• del Pilar Martin M, Cravens PD, Winger R et al. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch. Neurol.65(12), 1596–1603 (2008).
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Buijsse AO, van den Bremer ET et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat. Biotechnol.27(8), 767–771 (2009).
   PubMed Web of Science ®Google Scholar
• Miller DH, Khan OA, Sheremata WA et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med.348, 15–23 (2003).
   PubMed Web of Science ®Google Scholar
• Rispens T, Leeuwen A, Vennegoor A et al. Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody. Anal. Biochem.411(2), 271–276 (2011).
   PubMed Web of Science ®Google Scholar
• Sheremata WA, Vollmer TL, Stone LA, Willmer-Hulme AJ, Koller M. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology52(5), 1072–1074 (1999).
   PubMed Web of Science ®Google Scholar
• Rudick RA, Sandrock A. Natalizumab: 4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev. Neurother.4(4), 571–580 (2004).
   PubMedGoogle Scholar
• Tubridy N, Behan PO, Capildeo R et al. The effect of anti- 4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology53(3), 466–472 (1999).
   PubMed Web of Science ®Google Scholar
• Havrdova E, Galetta S, Stefoski D, Comi G. Freedom from disease activity in multiple sclerosis. Neurology74(Suppl. 3), S3–S7 (2010).
   Google Scholar
• Havrdova E, Galetta S, Hutchinson M et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing–Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol.8(3), 254–260 (2009).
   PubMed Web of Science ®Google Scholar
• Phillips JT, Giovannoni G, Lublin FD et al. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis. Mult. Scler. doi:10.1177/1352458511399611 (2011) (Epub ahead of print).
   Google Scholar
• Hellwig K, Schimrigk S, Fischer M et al. Allergic and nonallergic delayed infusion reactions during natalizumab therapy. Arch. Neurol.65(5), 656–658 (2008).
   PubMedGoogle Scholar
• Goodman AD, Rossman H, Bar-Or A et al. GLANCE: results of a Phase II, randomized, double-blind, placebo-controlled study. Neurology72(9), 806–812 (2009).
   PubMed Web of Science ®Google Scholar
• Wiendl H, Belachew S, Butzkueven H et al. Assessment of the association between baseline characteristics and postbaseline relapses, disability progression and improvement over time in the natalizumab (TYSABRI®) Observational Program (TOP) in patients with multiple sclerosis. Presented at: 63rd Congress of the American Academy of Neurology. Honolulu, Hawaii, USA, 9–16 April, 2011.
   Google Scholar
• Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol.9(4), 425–437 (2010).
   PubMed Web of Science ®Google Scholar
• Zohren F, Toutzaris D, Klärner V et al. The monoclonal anti-IN SITU-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood111(7), 3893–3895 (2008).
   PubMed Web of Science ®Google Scholar
• Monaco MC, Atwood WJ, Gravell M, Tornatore CS, Major EO. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. J. Virol.70(10), 7004–7012 (1996).
   PubMed Web of Science ®Google Scholar
• Bellucci R, De Propris MS, Buccisano F et al. Modulation of in situ-4 and L-selectin expression on normal CD34+ cells during mobilization with G-CSF. Bone Marrow Transplant23(1), 1–8 (1999).
   PubMed Web of Science ®Google Scholar
• Yaldizli O, Putzki N. Natalizumab in the treatment of multiple sclerosis. Ther. Adv. Neurol. Disord.2(2), 115–128 (2009).
   PubMedGoogle Scholar
• Warnke C, Menge T, Hartung HP et al. Natalizumab and progressive multifocal leukoencephalopathy. Arch. Neurol.67(8), 923–930 (2010).
   PubMed Web of Science ®Google Scholar
• Gorelik L, Lerner M, Bixler S et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann. Neurol.68(3), 295–303 (2010).
   PubMed Web of Science ®Google Scholar
• Bloomgren G, Sandrock A, Hotermans C et al. Risk stratification for progressive multifocal leukoencephalopathy in multiple sclerosis patients using natalizumab. Presented at: 21st Meeting of the European Neurological Society. Lisbon, Portugal, 28–31 May, 2011.
   Google Scholar
• Vermersch P, Kappos L, Gold R et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology76(20), 1697–1704 (2011).
   PubMed Web of Science ®Google Scholar
• Stüve O, Marra CM, Cravens PD et al. Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. Arch. Neurol.64(2), 169–176 (2007).
   PubMed Web of Science ®Google Scholar
• Brickelmaier M, Lugovskoy A, Kartikeyan R et al. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob. Agents Chemother.53(5), 1840–1849 (2009).
   PubMed Web of Science ®Google Scholar
• Elphick GF, Querbes W, Jordan JA et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science306(5700), 1380–1383 (2004).
   PubMed Web of Science ®Google Scholar
• Clifford D, Nath A, Cinque P et al. Mefloquine treatment in patients with progressive multifocal leukoencephalopathy. Presented at: 63rd Congress of the American Academy of Neurology. Honolulu, Hawaii, USA, 9–16 April 2011.
   Google Scholar
• O’Connor PW, Goodman AD, Kappos L et al. Updated efficacy and safety of natalizumab in patients who participated in the STRATA study. Presented at: 26th Congress of the European Committee for treatment and research in Multiple Sclerosis. Gothemburg, Sweden, 13–16 October 2010.
   Google Scholar
• Bergamaschi R, Montomoli C. Melanoma in multiple sclerosis treated with natalizumab: causal association or coincidence? Mult. Scler.15(12), 1532–1533 (2009).
   PubMed Web of Science ®Google Scholar
• Castela E, Lebrun-Frenay C, Laffon M et al. Evolution of nevi during treatment with natalizumab: a prospective follow-up of patients treated with natalizumab for multiple sclerosis. Arch. Dermatol.147(1), 72–76 (2011).
   PubMedGoogle Scholar
• Schweikert A, Kremer M, Ringel F et al. Primary central nervous system lymphoma in a patient treated with natalizumab. Ann. Neurol.66(3), 403–406 (2009).
   PubMed Web of Science ®Google Scholar
• Bozic C, LaGuette J, Panzara MA, Sandrock AW. Natalizumab and central nervous system lymphoma: no clear association. Ann. Neurol.66(3), 261–262 (2009).
   PubMed Web of Science ®Google Scholar
• Phan-Ba R, Bisig B, Deprez M et al. Primary central nervous system lymphoma in a patient treated with Natalizumab. Ann. Neurol.69(6), 1060–1061 (2011).
   PubMed Web of Science ®Google Scholar
• Bezabeh S, Flowers CM, Kortepeter C, Avigan M. Clinically significant liver injury in patients treated with natalizumab. Aliment Pharmacol. Ther.31(9), 1028–1035 (2010).
   PubMed Web of Science ®Google Scholar
• Wehner NG, Shopp G, Oneda S, Clarke J. Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an α4 integrin inhibitor. Birth Defects Res. B Dev. Reprod. Toxicol.86(2), 117–130 (2009).
   PubMed Web of Science ®Google Scholar
• Wehner NG, Shopp G, Osterburg I, Fuchs A, Buse E, Clarke J. Postnatal development in cynomolgus monkeys following prenatal exposure to natalizumab, an α4 integrin inhibitor. Birth Defects Res. B Dev. Reprod. Toxicol.86(2), 144–156 (2009).
   PubMed Web of Science ®Google Scholar
• Cristiano LM, Bozic C, Bloomgren G, Kooijmans-Coutinho M. Preliminary evaluation of prospective pregnancy outcomes from the TYSABRI® (natalizumab) pregnancy registry. Presented at: 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Gothemburg, Sweden, 13–16 October 2010.
   Google Scholar
• Ghezzi A, Pozzilli C, Grimaldi LM et al. Safety and efficacy of natalizumab in children with multiple sclerosis. Neurology75(10), 912–917 (2010).
   PubMed Web of Science ®Google Scholar
• Yeh EA, Weinstock-Guttman B. Natalizumab in pediatric multiple sclerosis patients. Ther. Adv. Neurol. Disord.3(5), 293–299 (2010).
   PubMedGoogle Scholar
• Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch. Neurol.68, 186–191 (2011).
   PubMedGoogle Scholar
• Vellinga MM, Castelijns JA, Barkhof F, Uitdehaag BM, Polman CH. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology70(13 Pt 2), 1150–1151 (2008).
   PubMed Web of Science ®Google Scholar
• O’Connor PW, Goodman A, Kappos L et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology76, 1858–1865 (2011).
   PubMed Web of Science ®Google Scholar
• Ghezzi A, Grimaldi LM, Marrosu MG et al. Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group – Italian Neurological Society. Neurol. Sci.32(2), 351–358 (2011).
   PubMedGoogle Scholar
• Cohen JA, Barkhof F, Comi G et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med.362, 402–415 (2010).
   PubMed Web of Science ®Google Scholar
• Kappos L, Bates D, Hartung HP et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol.6, 431–441 (2007).
   PubMed Web of Science ®Google Scholar